Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 15/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610111 | 0.82 | LIPE (0.57) | LIPEMETAP2MCHR1 | |
| SCHEMBL609124 | 0.81 | LIPE (0.53) | LIPEMCHR1MALT1 | |
| SCHEMBL608525 | 0.78 | LIPE (0.60) | LIPEMETAP2 | |
| SCHEMBL608386 | 0.77 | LIPE (0.53) | LIPEMETAP2 | |
| SCHEMBL610122 | 0.77 | LIPE (0.53) | LIPEMETAP2MCHR1 | |
| SCHEMBL609659 | 0.77 | LIPE (0.52) | LIPEEGLN1MALT1 | |
| SCHEMBL610020 | 0.76 | LIPE (0.54) | LIPEEGLN1 | |
| SCHEMBL609375 | 0.76 | LIPE (0.72) | LIPEMETAP2 | |
| SCHEMBL609591 | 0.76 | LIPE (0.59) | LIPE | |
| SCHEMBL608867 | 0.76 | LIPE (0.57) | LIPEMCHR1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | claimed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | claimed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | claimed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | LIPE 1/4885METAP2 3309/4885MCHR1 1090/4885 |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | LIPE 1/4885METAP2 3309/4885MCHR1 1090/4885 |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | LIPE 1/4885METAP2 3309/4885MCHR1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.